Last updated: June 23, 2026
FOUGERA (Fougera) Competitive Landscape Analysis: Market Position, Patent/Generic Risk, and Strategic Options
FOUGERA is not a single FDA-approved drug but a brand/manufacturer identifier used across multiple products (most commonly U.S. generic/OTC drugs by Fougera Pharmaceuticals/Teva as the holder/labeler on various SKUs). A patent-and-exclusivity landscape therefore requires a specific active ingredient, dosage form, and NDC to map to Orange Book listings, FDA approvals, and enforceable patent estates. With no drug-specific target, a complete, accurate competitive IP and regulatory analysis cannot be produced under strict patent-analytics rules.
Which “FOUGERA” products have exclusivity protection via FDA Orange Book listings?
Featured snippet answer: FOUGERA coverage is product-by-product; there is no single Orange Book “FOUGERA” listing that defines exclusivity protection across the company’s portfolio. Exclusivity and listed patents depend on the specific NDA/ANDA and labeled NDC.
What patents and exclusivities are typically tied to FOUGERA-labeled products
- New chemical entity (NCE) and 5-year exclusivity: only for qualifying NDAs.
- 3-year exclusivity: for new clinical investigations in many NDA supplements.
- Patent listings: composition-of-matter, formulation, method-of-use, and device-related patents where relevant.
- Exclusivity vs patents: Orange Book exclusivity blocks first generic entry even when patent coverage is narrower.
What breaks exclusivity
- Patent expiration (hard block).
- Expiration of exclusivity periods (soft block).
- Launch timing vs FDA “first applicant” exclusivity for ANDAs (where applicable).
- Paragraph IV litigation outcomes and settlements that trigger FDA eligibility dates.
When does “FOUGERA” lose market exclusivity and generic protection?
Featured snippet answer: You cannot determine a loss-of-exclusivity date without a named active ingredient and its FDA reference product (NDA/RS) plus the ANDA/NDC for the FOUGERA SKU.
Typical FOUGERA-facing timelines for generics
- If FOUGERA is the first generic entrant: 180-day ANDA exclusivity can block other generics.
- If FOUGERA is later entrant: timing depends on reference drug exclusivity and Orange Book patent expiry.
- If FOUGERA is an authorized generic through a settlement: launch dates tie to settlement triggers.
How many Orange Book patents cover FOUGERA-branded products vs reference drugs?
Featured snippet answer: Patent counts are product-specific; FOUGERA labels multiple SKUs that can have different Orange Book dynamics.
What drives patent-count variation
- Whether the reference product is brand-new vs mature.
- Whether patents cover formulation changes (extended-release, particle engineering).
- Method-of-use patents tied to specific dosing or patient subsets.
- Whether the FOUGERA product is a generic of an older NDA (fewer listed patents remain) or an authorized generic with settlement-driven scope.
What Paragraph IV challenges target FOUGERA-labeled drugs and their Orange Book patents?
Featured snippet answer: Paragraph IV challenges are filed against specific patents for specific ANDAs and reference products; “FOUGERA” alone does not identify a patent set.
What to look for in PAIR/ANDA litigation records
- Which ANDA applicant filed the Paragraph IV.
- Which listed patents were attacked (e.g., US comp, formulation, method-of-use).
- Whether there was a settlement and the agreed “section viii” eligibility date for other filers.
- Injunction or stipulated dismissal terms.
Which companies are challenging FOUGERA in FDA exclusivity and ANDA litigation?
Featured snippet answer: Competitors challenge by ANDA product mapping, not by “FOUGERA” label. Generic challengers are identifiable only after linking the FOUGERA SKU to its FDA reference product and then searching ANDA litigation for that NDA.
What formulations and dosage forms are protected for FOUGERA products?
Featured snippet answer: Formulation and manufacturing protections are assigned to specific patents for specific dosage forms. FOUGERA brand identity does not define which formulation patents exist.
Common formulation patent themes
- Extended-release matrix patents and coating systems.
- Solubilization, polymorph, salt form, and particle size.
- Bioequivalence-supporting release profiles that can be patented as process or composition.
What method-of-use patents restrict generic entry for FOUGERA products?
Featured snippet answer: Method-of-use patents are relevant only where the reference product’s claims were listed for that NDA and are still within term.
How method-of-use affects the generic “skinny label” strategy
- If method-of-use patents cover specific indications, generic labels may need carve-outs.
- If carve-outs shrink the market too much, generics often file full-label or pursue settlements.
How does FOUGERA’s patent estate strength compare with other generic manufacturers?
Featured snippet answer: FOUGERA’s strength is not a single metric. For each FOUGERA SKU, strength depends on:
- whether FOUGERA holds any relevant patents,
- whether it is a labeler/holder vs a licensee,
- whether patents remain in force and are listed in the Orange Book for the reference product.
Generic-market strength indicators (product-specific)
- Launch timing advantage based on Paragraph IV outcomes.
- Manufacturing/process barriers.
- Settlement scope and carve-outs.
- FDA inspection outcomes that affect supply continuity.
What FDA regulatory status does FOUGERA hold for each competitive product?
Featured snippet answer: Regulatory status must be SKU-linked:
- NDA vs ANDA
- approval date
- labeling (full vs carve-out)
- REMS (rare for most generics)
- whether it is an OTC monograph product vs prescription NDA/ANDA
What patent litigation affects FOUGERA products and what settlements changed launch dates?
Featured snippet answer: Litigation and settlements are tied to specific ANDAs/NDA reference products. “FOUGERA” as a labeler does not uniquely define a litigation docket.
Which generic entry risks exist for FOUGERA-branded SKUs?
Featured snippet answer: Entry risk is primarily driven by:
- proximity to patent expiry or exclusivity expiry
- whether any remaining patents are still enforceable and listed
- likelihood of another ANDA filer with a Paragraph IV strategy
Risk categories
- High risk: near patent expiry and active Paragraph IV filings.
- Medium risk: patents exist but are likely to be narrow or vulnerable.
- Low risk: long runway with weak generic claim coverage or stable settlement.
Revenue exposure: how much FOUGERA portfolio is at risk from generic launches?
Featured snippet answer: This requires product-level mapping (active ingredients, strengths, NDCs) and sales/revenue attribution by SKU. Without that, revenue exposure cannot be quantified.
Key Takeaways
- FOUGERA is not a single drug entity for patent and Orange Book analysis; it is a label/manufacturer identifier used across multiple products.
- A complete competitive landscape for FOUGERA requires SKU-level mapping to FDA approvals (NDA/ANDA), Orange Book patent listings, and product-specific litigation.
- Without an identified active ingredient and dosage form, there is no defensible way to provide patent counts, expiration dates, Paragraph IV challenges, settlement launch triggers, or regulatory status.
FAQs
-
How do I assess exclusivity risk for a FOUGERA-labeled product without knowing the NDA/ANDA reference?
Link the FOUGERA NDC to the FDA reference product and Orange Book entry; exclusivity is defined at the reference product level, not by labeler name.
-
Do FOUGERA products have 180-day ANDA exclusivity?
Some may, but it depends on whether the FOUGERA filer is the first Paragraph IV generic for the reference NDA and whether forfeiture rules apply.
-
What’s the difference between Orange Book patent protection and FDA exclusivity for FOUGERA SKUs?
Orange Book lists patents that can be enforced via the Hatch-Waxman framework; FDA exclusivity is a separate block based on NDA/ANDA exclusivity periods.
-
How do formulation patents impact “authorized generic” strategies for FOUGERA?
Authorized generics still face the same listed patent landscape for the reference product unless settlement terms narrow patent scope or define launch eligibility.
-
What typically drives settlement terms for ANDA challenges involving FOUGERA-labeled products?
Settlement dates align to patent expiry, at-risk launch eligibility, and scope of labeling carve-outs tied to the attacked patents/indications.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- FDA. Drug Patents and Exclusivity. FDA.
- FDA. Paragraph IV ANDA litigation and Hatch-Waxman framework resources. FDA.
